Results 61 to 70 of about 30,994 (308)
Introduction: Mounting evidence suggests that glucagon-like-peptide-1 receptor-agonists (GLP-1 RAs) attenuate cardiovascular-risk in type-2 diabetes (T2DM). Tirzepatide is the first-in-class, dual glucose-dependent-insulinotropic-polypeptide GIP/GLP-1 RA
Maria-Ioanna Stefanou +13 more
semanticscholar +1 more source
SuFEx‐Enabled Reprogramming of Flavonoids for Selective α‐Glucosidase Covalent Inhibition
Selective inhibition of intestinal α‐glucosidase remains limited by poor enzyme specificity and off‐target metabolic effects. Here, SuFEx click chemistry is used to reprogram natural flavonoids into covalent inhibitors with enhanced α‐glucosidase selectivity and controlled reactivity. This strategy enables effective regulation of carbohydrate digestion
Fengyu Guo +14 more
wiley +1 more source
The Spatiotemporal Genetic Architecture of Seed Vigor in Upland Cotton
Leveraging the semi‐automated SeedRanger platform, we profiled the germination kinetics of 356 cotton accessions at a 30‐min interval. This high‐throughput phenomic approach delineated a temporal genetic network comprising 541 stage‐specific loci. Crucially, functional validation identified FLA2 as a pivotal, auxin‐modulated regulator that orchestrates
Luyao Wang +32 more
wiley +1 more source
The evolution of the therapeutic concept ‘GIP receptor antagonism’
Glucose-dependent insulinotropic polypeptide (GIP) is an intestinal hormone that potentiates glucose-induced insulin secretion in the postprandial state. GIP exerts a broad range of other physiological actions e.g.
Frederikke Koefoed-Hansen +9 more
doaj +1 more source
Introduction Sleep disturbances are increasingly recognized as a risk factor for Alzheimer's disease. However, no study has assessed the relationships between objective sleep fragmentation (SF) and brain and cognitive integrity across different cognitive
Claire André +10 more
doaj +1 more source
Incretin-based therapies for cardio-kidney-liver-metabolic disease: the role of the liver in the modern era of chronic disease management [PDF]
Steatotic liver disease (SLD) is a leading cause of disease globally and demands new therapeutic approaches to mitigate underlying metabolic dysregulation. Incretin-based therapies are emerging as a viable prospect to fulfil this unmet niche.
Harendran Elangovan +7 more
doaj +1 more source
Hypothalamic Control of Liver Health and Disease: From Circuits to Pathophysiology and Therapies
This review delineates the hypothalamic circuits that control liver homeostasis via autonomic and neuroendocrine pathways. Dysregulation of this hypothalamus–liver axis drives disease progression across a spectrum including steatotic liver disease, liver inflammation and injury, fibrosis, cirrhosis, and hepatocellular carcinoma.
Qin Tang +7 more
wiley +1 more source
The absence of an ideal medicine for the treatment of patients with type 2 diabetes, that would be able to provide not only high quality and constant monitoring of glycemia without increasing body weight, with no risk of hypoglycemia, with no negative ...
T. V. Saprina +5 more
doaj +1 more source
Gastric inhibitory polypeptide (GIP) is selectively decreased in the roux-limb of dietary obese mice after RYGB surgery. [PDF]
Gastric inhibitory polypeptide (GIP, glucose-dependent insulinotropic polypeptide) is expressed by intestinal K cells to regulate glucose-induced insulin secretion. The impact of Roux-en Y bypass (RYGB) surgery on blood GIP is highly contraversial.
Jiaqiang Zhou +4 more
doaj +1 more source
As engineered nanomaterials gain prominence in cancer imaging and therapy, understanding their impact on tumor progression becomes increasingly critical. We demonstrate that gold and silica‐coated gold nanomaterials can either suppress or enhance breast cancer metastasis through distinct tumor microenvironment interactions, while identifying ...
Kiana Buttiens +11 more
wiley +1 more source

